We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Diagnostic Test Assesses Suitability for Immune Checkpoint Inhibitor Immunotherapy

By LabMedica International staff writers
Posted on 08 Sep 2020
A newly developed diagnostic procedure enables doctors to predict whether a cancer patient will benefit from immune checkpoint inhibitor immunotherapy.

Checkpoint inhibitor therapy is a form of cancer immunotherapy, which targets immune checkpoints, key regulators of the immune system that when stimulated can dampen the immune response to an immunologic stimulus. More...
Some cancers can protect themselves from immune attack by stimulating immune checkpoint targets, and checkpoint therapy can block inhibitory checkpoints, restoring immune system function.

PD-1 is the transmembrane programmed cell death 1 protein, which interacts with PD-L1 (PD-1 ligand 1). PD-L1 on the cell surface binds to PD-1 on an immune cell surface, which inhibits immune cell activity. Among PD-L1 functions is a key regulatory role on T-cell activities. It appears that (cancer-mediated) upregulation of PD-L1 on the cell surface may inhibit T-cells that might otherwise attack the cancer cell. Antibodies that bind to either PD-1 or PD-L1, and therefore block the interaction, may allow T-cells to attack the tumor.

While checkpoint inhibitor immunotherapy has proven to be quite successful in some patients, in others it has demonstrated little or no effect. Given the inherent toxicity of these treatments, is necessary to define which patients are most likely to benefit from them, avoiding unnecessary exposure to those who will not. In this regard, investigators at the University of Bath (United Kingdom) addressed the issue of a patient’s suitability for immune checkpoint treatment.

The investigators quantitatively imaged PD-1/PD-L1 interactions in tumor biopsy specimens from patients, employing an assay that readily detected these intercellular protein-protein interactions in the 10 nanometer range. Results of these analyses across multiple patient cohorts demonstrated the inter-cancer, inter-patient, and intra-tumoral heterogeneity of interacting immune checkpoints. While the PD-1/PD-L1 interaction was not correlated with clinical PD-L1 expression scores in malignant melanoma, among anti-PD-1 treated metastatic non-small-cell lung carcinoma (NSCLC) patients, those with lower PD-1/PD-L1 interaction had significantly worsened survival.

Senior author Dr. Banafshé Larijani, director of the Centre for Therapeutic Innovation at the University of Bath, said, "Currently, decisions on whether to proceed with checkpoint inhibitor treatment are based simply on whether PD-1 and PD-L1 are present in biopsies, rather than their functional state. However our work has shown it is far more important to know that the two proteins are actually interacting and therefore likely to be having a functional impact on tumor survival."

The immune checkpoint paper was published in the August 27, 2020, online edition of the journal Cancer Research.

Related Links:
University of Bath


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.